Drugs / SFA002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05642182 | Mar 2022 → Jul 2025 overdue | psoriasis | SFA Therapeutics | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06863493 | Jun 2025 → Jun 2026 overdue | psoriasis | SFA Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SFA002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06863493 ↗ |
| Route | Oral | “oral SFA002 treatment” NCT06863493 ↗ |